News

NephroSant Launches Two-Year Study of 2,000 Kidney Transplant Recipients

 NephroSant, Inc. a biotechnology company dedicated to accelerating the assessment of early kidney damage with a mission to significantly improve global kidney health, announced the first patient has been enrolled into the Assessment of QSant™ for Underlying Allograft Rejection (AQUA) study. 

Pionyr Doses First Patient in Expansion Study

Pionyr Immunotherapeutics, a company founded by pathologist researcher Max Krummel from the University of California, is developing first-in-class Myeloid TuningTM antibody therapeutics that enhance the body's antitumor immunity by altering, or "tuning", immune cells within the tumor...

Akili Interactive Cracks The Top Ten

Akili Interactive makes Fast Company's top ten list for developing a digital therapeutic for ADHD. MORE

QSent Improves the Detection of Early Kidney Rejection

"We developed QSant to aid physicians in the early detection of rejection in order to protect patients from an untimely loss of a transplanted kidney" explained NephroSant Founder and University of California professor, Minnie Sarwal, MD, PhD. "Results from this RWD study provide important insights...

Video Game Improves Brain Function

EndeavorRx, the startup founded by UCSF neuroscientist Adam Gazzaley, has been cleared to help in improving attention function as measured by computer-based testing in children ages 8-12 years who have primarily inattentive or combined-type ADHD who struggle with maintaining attention. MORE

Alessa Therapeutics Announces First Patient Enrollment in Biolen®+RT Study in Collaboration with the National Cancer Institute

Dr.

Health Canada Allows ELEGANSE Trial for the Treatment of Lennox-Gastaut Syndrome

Epygenix Therapeutics, a clinical-stage biopharmaceutical company founded on UCSF researcher Scott Baraban's work and focused on rare and intractable genetic epilepsy, announced today that Health Canada issued a "No Objection Letter" (NOL) to proceed with the ELEGANSE trial for the treatment of...

UCSF Gets New Money to Study the 'Galaxies' Within You (Your Microbes)

This month the University of California at San Francisco for research about the human microbiome received $25 million to study them. Susan Lynch will direct the Benioff Center for Microbiome Medicine at UCSF.

Siolta Therapeutics Awarded NIH Grant

Siolta Therapeutics, a clinical-stage biopharmaceutical company developing novel microbiome-based targeted therapeutics developed by UCSF researcher Dr. Susan Lynch, today announced that it was awarded an Advanced Technology Small Business Innovation Research (SBIR) grant by the National Institute...

New CRISPR tool maps out routes to better immune cell therapies for cancer, autoimmune diseases

The CRISPR gene-editing system has offered scientists a powerful tool for studying the effects of altering specific genes. Now, researchers at the Gladstone-UCSF Institute of Genomic Immunology have devised a CRISPR platform that allowed them to discover new roles of genes in human T cells, which...